首页 | 本学科首页   官方微博 | 高级检索  
     

联合紫杉醇化疗晚期恶性肿瘤24例
引用本文:张小华,罗伟炎,罗雄辉,陈育文. 联合紫杉醇化疗晚期恶性肿瘤24例[J]. 赣南医学院学报, 2002, 22(5): 522-523
作者姓名:张小华  罗伟炎  罗雄辉  陈育文
作者单位:广东兴宁市人民医院肿瘤科,广东,兴宁,514500;广东兴宁市人民医院肿瘤科,广东,兴宁,514500;广东兴宁市人民医院肿瘤科,广东,兴宁,514500;广东兴宁市人民医院肿瘤科,广东,兴宁,514500
基金项目:梅州市医药卫生科研课题基金资助
摘    要:目的:评价联合紫杉醇化疗晚期恶性肿瘤的疗效.方法:观察对象为肺癌10例,乳腺癌8例,卵巢癌5例,鼻咽癌1例.联合化疗方案中紫杉醇135mg/m2,静滴3小时,4周1个疗程,共2~3周期,其它药物为卡铂、吡柔比星等.结果:总有效率71%,不良反应主要为骨髓抑制、脱发、恶心、呕吐.结论:联合紫杉醇化疗肺癌、乳腺癌、卵巢癌等疗效确切,不良反应可以耐受.

关 键 词:紫杉醇  恶性肿瘤
文章编号:1001-5779(2002)05-0522-02
修稿时间:2002-11-13

Combined Chemotherapy of Paclitaxel and Others for 24 Patients with Malignant Tumor
ZHANG Xiao hua,et al. Combined Chemotherapy of Paclitaxel and Others for 24 Patients with Malignant Tumor[J]. Journal of Gannan Medical College, 2002, 22(5): 522-523
Authors:ZHANG Xiao hua  et al
Abstract:Objective:To evaluate the effcicacy of Pactitaxel on advanced malignant tumor.Methods:To observe 10 cases with lung cancer,8 casese with breast cancer,5 cases with ovarian cancer and 1 case with nasopharyngeal carcinoma.24 patients were treated by combination chemotherapy of pactitaxel 135mg/m 2,combined with carboplatin or pirarubin was given intravenously for three hours.Each vegimen included 2 to 3 cycle and it was repeated every four weeks.Result:A total response rate for 24 patients was 71%.The major side effects wree tolerable antitumor agent in treatment of lung cancer,breast cancer or ovarian cancer.
Keywords:Paclitaxel  mailgnant tumor
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号